IL102297A - Mark disease vaccine containing a viral agent selected from a comet of diluted revertant virus - Google Patents
Mark disease vaccine containing a viral agent selected from a comet of diluted revertant virusInfo
- Publication number
- IL102297A IL102297A IL10229792A IL10229792A IL102297A IL 102297 A IL102297 A IL 102297A IL 10229792 A IL10229792 A IL 10229792A IL 10229792 A IL10229792 A IL 10229792A IL 102297 A IL102297 A IL 102297A
- Authority
- IL
- Israel
- Prior art keywords
- virus
- vaccine
- chickens
- viral agent
- clones
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title claims abstract description 117
- 229960005486 vaccine Drugs 0.000 title claims abstract description 61
- 230000002238 attenuated effect Effects 0.000 title claims abstract description 25
- 208000006758 Marek Disease Diseases 0.000 title claims abstract description 11
- 230000003612 virological effect Effects 0.000 title claims description 18
- 241000287828 Gallus gallus Species 0.000 claims description 58
- 241000701047 Gallid alphaherpesvirus 2 Species 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 239000000427 antigen Substances 0.000 claims description 7
- 102000036639 antigens Human genes 0.000 claims description 7
- 108091007433 antigens Proteins 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 239000013604 expression vector Substances 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 3
- 230000003053 immunization Effects 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229940031626 subunit vaccine Drugs 0.000 claims description 2
- 230000028993 immune response Effects 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 230000007918 pathogenicity Effects 0.000 abstract description 9
- 230000002163 immunogen Effects 0.000 abstract description 7
- 230000000890 antigenic effect Effects 0.000 abstract description 5
- 229940031348 multivalent vaccine Drugs 0.000 abstract description 4
- 230000005847 immunogenicity Effects 0.000 abstract description 3
- 235000013330 chicken meat Nutrition 0.000 description 56
- 230000003902 lesion Effects 0.000 description 32
- 241000271566 Aves Species 0.000 description 17
- 241001502481 Meleagrid alphaherpesvirus 1 Species 0.000 description 17
- 230000008774 maternal effect Effects 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 13
- 206010058874 Viraemia Diseases 0.000 description 11
- 230000001681 protective effect Effects 0.000 description 11
- 238000004113 cell culture Methods 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 230000010076 replication Effects 0.000 description 7
- 238000002255 vaccination Methods 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 238000000692 Student's t-test Methods 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 230000001018 virulence Effects 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 244000144977 poultry Species 0.000 description 4
- 235000013594 poultry meat Nutrition 0.000 description 4
- 238000012353 t test Methods 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 229940031416 bivalent vaccine Drugs 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 239000002054 inoculum Substances 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 210000001161 mammalian embryo Anatomy 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000003362 replicative effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 241001529453 unidentified herpesvirus Species 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 241001314440 Triphora trianthophoros Species 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012809 post-inoculation Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000015541 sensory perception of touch Effects 0.000 description 2
- 240000005369 Alstonia scholaris Species 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 241000581364 Clinitrachus argentatus Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000042032 Petrocephalus catostoma Species 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229940031567 attenuated vaccine Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000011072 cell harvest Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000003837 chick embryo Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- SWXVUIWOUIDPGS-UHFFFAOYSA-N diacetone alcohol Natural products CC(=O)CC(C)(C)O SWXVUIWOUIDPGS-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- XLSMFKSTNGKWQX-UHFFFAOYSA-N hydroxyacetone Chemical compound CC(=O)CO XLSMFKSTNGKWQX-UHFFFAOYSA-N 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
- C12N2710/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/723,037 US5849299A (en) | 1991-06-28 | 1991-06-28 | Attenuated revertant serotype 1 marek's disease vaccine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL102297A0 IL102297A0 (en) | 1993-01-14 |
| IL102297A true IL102297A (en) | 1996-09-12 |
Family
ID=24904551
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL10229792A IL102297A (en) | 1991-06-28 | 1992-06-24 | Mark disease vaccine containing a viral agent selected from a comet of diluted revertant virus |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US5849299A (de) |
| EP (1) | EP0591384B1 (de) |
| JP (1) | JPH06508634A (de) |
| KR (1) | KR940701272A (de) |
| AT (1) | ATE175120T1 (de) |
| AU (1) | AU669849B2 (de) |
| CA (1) | CA2112225C (de) |
| DE (1) | DE69228063D1 (de) |
| IL (1) | IL102297A (de) |
| MX (1) | MX9203436A (de) |
| NZ (1) | NZ243251A (de) |
| WO (1) | WO1993000112A1 (de) |
| ZA (1) | ZA924654B (de) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL114501A (en) * | 1994-07-14 | 1999-08-17 | Akzo Nobel Nv | Marek's disease virus vaccine |
| EP0703294A1 (de) * | 1994-07-14 | 1996-03-27 | Akzo Nobel N.V. | Virusimpfstoff gegen Mareksche Krankheit |
| US6475770B1 (en) | 1997-06-10 | 2002-11-05 | Pfizer, Inc. | Processes for preparation of Marek's Disease using continuous mammalian cell lines |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL8401120A (nl) * | 1984-04-09 | 1985-11-01 | Centraal Diergeneeskundig Inst | Viruspreparaat, waarmee gevaccineerd kan worden tegen de ziekte van marek. |
| US4895717A (en) * | 1987-07-10 | 1990-01-23 | The United States Of America As Represented By The Secretary Of Agriculture | Revertant serotype 1 Marek's disease vaccine |
| FR2666589B1 (fr) * | 1990-09-07 | 1994-08-05 | Rhone Merieux | Nouveaux virus herpes recombinants, vaccin a base de ces recombinants, leur procede de preparation, genes, vecteurs et plasmides utilises dans ce procede. |
-
1991
- 1991-06-28 US US07/723,037 patent/US5849299A/en not_active Expired - Lifetime
-
1992
- 1992-06-22 NZ NZ243251A patent/NZ243251A/xx not_active IP Right Cessation
- 1992-06-24 IL IL10229792A patent/IL102297A/en not_active IP Right Cessation
- 1992-06-24 ZA ZA924654A patent/ZA924654B/xx unknown
- 1992-06-26 WO PCT/US1992/005249 patent/WO1993000112A1/en not_active Ceased
- 1992-06-26 MX MX9203436A patent/MX9203436A/es not_active Application Discontinuation
- 1992-06-26 KR KR1019930704068A patent/KR940701272A/ko not_active Ceased
- 1992-06-26 EP EP92914115A patent/EP0591384B1/de not_active Expired - Lifetime
- 1992-06-26 AU AU22406/92A patent/AU669849B2/en not_active Expired
- 1992-06-26 JP JP5501596A patent/JPH06508634A/ja active Pending
- 1992-06-26 DE DE69228063T patent/DE69228063D1/de not_active Expired - Lifetime
- 1992-06-26 AT AT92914115T patent/ATE175120T1/de not_active IP Right Cessation
- 1992-06-26 CA CA002112225A patent/CA2112225C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CA2112225C (en) | 2003-08-19 |
| EP0591384B1 (de) | 1998-12-30 |
| EP0591384A1 (de) | 1994-04-13 |
| KR940701272A (ko) | 1994-05-28 |
| CA2112225A1 (en) | 1993-01-07 |
| AU2240692A (en) | 1993-01-25 |
| WO1993000112A1 (en) | 1993-01-07 |
| NZ243251A (en) | 1993-11-25 |
| ATE175120T1 (de) | 1999-01-15 |
| MX9203436A (es) | 1994-06-30 |
| IL102297A0 (en) | 1993-01-14 |
| EP0591384A4 (de) | 1995-01-18 |
| DE69228063D1 (de) | 1999-02-11 |
| JPH06508634A (ja) | 1994-09-29 |
| ZA924654B (en) | 1993-03-31 |
| AU669849B2 (en) | 1996-06-27 |
| US5849299A (en) | 1998-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Schat et al. | Characterization of an apparently nononcogenic Marek's disease virus | |
| JP5508252B2 (ja) | 鳥インフルエンザ遺伝子を含有する組み換え七面鳥ヘルペスウイルス | |
| MORIMURA et al. | Pathogenesis of Marek's disease (MD) and possible mechanisms of immunity induced by MD vaccine | |
| EP0079597B1 (de) | Impfstoff und Verfahren zur Impfung gegen Herpes Simplex Virus (Typen 1 und 2) | |
| Muskett et al. | Increased virulence of an infectious bursal disease live virus vaccine after passage in chicks | |
| EP0125245B1 (de) | Kultivierung von hämorrhagische enteritis hervorrufenden viren in truthahn-gewebe-zellkulturen | |
| AU574164B2 (en) | Marek,s disease vaccine | |
| US5686287A (en) | Marek's disease virus vaccine | |
| JP3045609B2 (ja) | 抗マレック病組み換えフォウルポックスウィルス | |
| Peeters et al. | Non-transmissible pseudorabies virus gp50 mutants: a new generation of safe live vaccines | |
| US4895717A (en) | Revertant serotype 1 Marek's disease vaccine | |
| RU2329060C2 (ru) | Способ получения непрерывной клеточной линии и ее применение | |
| RU2126268C1 (ru) | Вакцина для профилактики инфекционного заболевания сумки у цыплят, лиофилизированная вирусная композиция, способ защиты цыплят от этого заболевания и способ получения живой вакцины | |
| US4895718A (en) | Serotype 2 Marek's disease vaccine | |
| US5849299A (en) | Attenuated revertant serotype 1 marek's disease vaccine | |
| JPH11509099A (ja) | マレック病ウイルス遺伝子およびマレック病に対する防御のためのワクチンにおけるそれらの使用 | |
| US5565202A (en) | Low enhancement serotype 2 vaccine for marek's disease | |
| JPH07504897A (ja) | ネコ感染性腹膜炎ワクチンおよび調製方法 | |
| EP0156478A2 (de) | Vermehrung von Gruppe II-Geflügeladeno-(AA)-Viren in Geflügelzellkulter und damit hergestellter Impfstoff | |
| Finkelstein et al. | Churchill, AE et al.(69) J. Gen. Virol. 4: 557—564. Sharma, JM et al.(82) Avian Dis. 26: 860—870. | |
| Hirai | United States Patent po | |
| US5436005A (en) | Low virulence infectiouns laryngotracheitis (ILT) virus for vaccinating birds | |
| CN109234315A (zh) | 一种表达传染性法氏囊病毒vp2基因的重组火鸡疱疹病毒株 | |
| AU647404B2 (en) | Low virulence laryngotracheitis (ILT) virus for vaccinating birds | |
| Hirano | Plaque assay and propagation in rat cell line LBC cells of rat coronavirus and 5 strains of sialodacryoadenitis virus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| RH | Patent void | ||
| NE | Application for restoration - patent lapsed through non-payment of renewal fees (section 60, patents law, 5727-1967) | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| EXP | Patent expired |